Loading...

Clincial Study Patient Recruitment and Site Engagement

Metastatic Prostate Cancer

Stark Raving Branding and Digital Marketing

Continuing The Fight Against Metastatic Prostate Cancer

SponsorBavarian Nordic

 

IndicationProstate Cancer

 

MaterialsPatient Education

 Site Staff Materials

 Referring Physician

 Patient Retention






The PROSPECT study was a randomized, double-blind, Phase 3 efficacy study of an investigational vaccine (PROSTVAC) ± GM-CSF in men with metastatic, castrate-resistant prostate cancer (mCRPC). Administered during seven treatment visits over five months, these immunizations – delivered by subcutaneous injection along with adjuvant GM-CSF or placebo – were designed to generate immune responses directed against prostate cancer cells.

The investigational vaccine (PROSTVAC) was the result of more than 15 years of poxviral vector development and evaluation. It was a novel candidate prostate cancer immunotherapy for the treatment of prostate cancer – administered subcutaneously during seven treatment visits over five months, along with GM-CSF or placebo.
Stark Raving Branding and Digital Marketing

Let's talk about your next project
To discuss an upcoming project or to learn more about our services, please contact us.

Be sure you complete all fields. Thank you!